Pfizer Expects Menstrually-Associated Migraine Claim For Relpax
Executive Summary
Pfizer expects Relpax (eletriptan) to be the first triptan to receive a labeling claim for relief of menstrually-associated migraines.
You may also be interested in...
Novartis’ Enablex To Enter Crowded Urinary Incontinence Market In Early ‘05
Novartis plans to enter the urinary incontinence market in early 2005 with the launch of its newly approved overactive bladder therapy Enablex
Novartis’ Enablex To Enter Crowded Urinary Incontinence Market In Early ‘05
Novartis plans to enter the urinary incontinence market in early 2005 with the launch of its newly approved overactive bladder therapy Enablex
Pfizer Darifenacin Will Be Divested As Condition For EU Approval Of Merger
Pfizer's pending urinary incontinence therapy darifenacin is the most significant asset the company needs to divest as a condition of the European approval of the Pharmacia merger